Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), OrthoPediatrics (KIDS) and BioNano Genomics (BNGO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Esperion (ESPR – Research Report), OrthoPediatrics (KIDS – Research Report) and BioNano Genomics (BNGO – Research Report) with bullish sentiments.

Esperion (ESPR)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Esperion, with a price target of $14.00. The company’s shares closed last Tuesday at $8.49.

According to TipRanks.com, Butler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.9% and a 38.5% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.

Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $12.33, representing a 54.7% upside. In a report released today, Needham also maintained a Buy rating on the stock with a $12.00 price target.

See today’s best-performing stocks on TipRanks >>

OrthoPediatrics (KIDS)

Needham analyst Michael Matson maintained a Buy rating on OrthoPediatrics today and set a price target of $50.00. The company’s shares closed last Tuesday at $38.64, close to its 52-week low of $36.71.

According to TipRanks.com, Matson is a 1-star analyst with an average return of -0.7% and a 45.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Currently, the analyst consensus on OrthoPediatrics is a Strong Buy with an average price target of $58.17, representing a 45.0% upside. In a report issued on October 17, Truist Financial also maintained a Buy rating on the stock with a $52.00 price target.

BioNano Genomics (BNGO)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics, with a price target of $6.00. The company’s shares closed last Tuesday at $2.38.

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -40.2% and a 13.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

BioNano Genomics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ESPR:

• Blue Line Protection Group Inc. Announces Expansion of Operations in New Mexico.
• Denali Therapeutics (DNLI) Receives a Buy from Berenberg Bank
• Intercept Pharma (ICPT) Gets a Hold from JMP Securities
• JMP Securities Sticks to Their Buy Rating for BioCryst (BCRX)
• JonesTrading Reaffirms Their Hold Rating on Aileron Therapeutics (ALRN)